DHA LABORATORY

Sample Patient

Date of Birth: **Gender:**

Specimen ID: **Control ID:** **Account Number:** **Status:** Final

Specimen Details:
Collection Date:
Report Date:

Patient ID:
Alt. Patient ID:

Physician Details:
Provider:
NPI Number:

Ordered Items: Ceruloplasmin; Copper, Serum; Histamine Determination, Blood; Plasma Zinc

Test Name	Result	LabCorp Reference Range	Result	Walsh/Pfeiffer Functional Range	Flag	Units	Lab
Ceruloplasmin							
• Ceruloplasmin	18	16.0-31.0				mg/dL	02
Copper, Serum							
• Copper, Serum	83	69-132	83	70-110		ug/dL	01
Detection Limit = 5							
Histamine Determination, Blood							
• Histamine Determination, Blood	79	12-127	79	40-70		ng/mL	01
Results for this test are for research purposes only by the assay's manufacturer. The performance characteristics of this product have not been established. Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.							
Plasma Zinc							
• Plasma Zinc	90	56-134	90	90-135		ug/dL	01
Detection Limit = 5							

DHA Laboratory
411 E Business Center Dr #107, Mt Prospect, IL 60056

Email: info@dhalab.com | **Phone**: 847-222-9546 | **Fax**: 847-222-9547

***NOTE:** The reference range(s) listed on this report are different than functional ranges. When determining biochemical imbalances based on the Carl Pfeiffer M.D./William Walsh Ph.D. model; Optimal functional ranges represent a range within a reference range that can position a patient within biochemical classes: (1) elevated histamine (2) low histamine (3) excess copper (4) zinc deficiency. Optimal functional ranges for patients may vary based on diagnosis, clinical features and response to treatment.

Laboratory Director: Judith Bowman, MD | CLIA #: 14D0995837

Reference Testing Facilities:

Lab	Lab Name and Address	Lab Phone Numbers	Lab Medical Director
01	Labcorp Burlington, 1447 York Court, Burlington NC 272153361	8007624344	Nagendra, Sanjai MD
02	Labcorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego CA 921284108	8586683700	Galloway, Jenny R MD

DHA LABORATORY

LABORATORY REPORT

Kryptopyrrole / Hydroxyhemopyrrolin-2-one (HPL)

Quantitative Urine Report

DHA LABORATORY | CLIA # 14D0995837

RESULT

5.10

mcg/dL

Optimal

PATIENT INFORMATION

PATIENT LAST NAME	FIRST NAME	M.I.	DATE OF BIRTH
Last name	First name	M.I.	mm/dd/yyyy

SEX: ◯ Male ◯ Female

PRACTITIONER: Dr.

DATES

DATE TESTED	DATE / TIME COLLECTED	DATE REPORTED
mm/dd/yyyy	mm/dd/yyyy, --:-- --	mm/dd/yyyy

COLLECTION NOTES

- ☐ Patient not taking supplements for 12–24 hours prior to testing
- ☐ Patient taking supplements for 12–24 hours prior to testing
- ☐ Additional Comments: Enter comments here...

TEST RESULT

Procedure: Kryptopyrrole (Hydroxyhemopyrrolin-2-one (HPL))

RESULT

5.10 mcg/dL

SPECIFIC GRAVITY

1.011

● **Result is within Optimal range (0–10.99 mcg/dL)**



CLASSIFICATION	RANGE
OPTIMAL	0–10.99 mcg/dL
BORDERLINE	11–15.99 mcg/dL
ELEVATED	≥ 16 mcg/dL

Pyrroles can vary based on the concentration of urine. This Kryptopyrrole result compensates for the concentration of the urine specimen.

Judith Bowman MD
Laboratory Director

T 847.222.9546 | F 847.222.9547
E results@dhalab.com
W www.DHALab.com

DHA LABORATORY

LABORATORY REPORT

Kryptopyrrole / Hydroxyhemopyrrolin-2-one (HPL)

Quantitative Urine Report

DHA LABORATORY | CLIA # 14D0995837

CLINICAL PATHWAY — ELEVATED KRYPTOPYRROLE



Additional Clinical Manifestations

- Hair Loss
- Dry eyes
- White Spots on Fingernails
- Impaired Immune functions
- Skin Rash
- Slow Growth/Delayed puberty
- Fatigue
- Anemia
- Nerve Problems (Pins and needles) in hands and feet
- Poor Wound Healing
- Poor Stress control
- Abnormal fat distribution
- "Fruity" breath and/or Body odor
- Morning Nausea
- Spleen-area Pain
- Joint pains
- Sensitivity to light and Noise
- Preference for spicy foods

KEY

- Clinical Manifestations of Pyrrole Disorder
- Elevated
- Decreased
- Neurotransmitter
- Fatty Acids Nutrient - Relationship
- Ionotropic Glutamate Receptor
- (Co)Enzyme/Vitamin

RETESTING SCHEDULE

TEST	RECOMMENDATION
Kryptopyrrole Quantitative Urine	3–4 Months

These findings should be evaluated in the context of the patient's comprehensive clinical profile, including relevant history and presenting symptoms, and are subject to the interpretive judgment of the treating medical professional.

Judith Bowman MD
Laboratory Director

T 847.222.9546 | F 847.222.9547
E results@dhalab.com
W www.DHALab.com